ABBV · News · 20261105N
Licensing / Collaboration Deals
AbbVie Inc. · 2026-11-05 · Importance 52 · Surprise 42 · In source text
AbbVie entered a global licensing agreement with Nxera Pharma for NXE0033744, an investigational oral EP4 receptor agonist for inflammatory bowel disease. AbbVie will pay $100 million upfront, with Nxera eligible for up to an additional $1.37 billion in development and commercial milestones, plus tiered royalties. The agreement expands the companies’ existing relationship and covers a molecule designed to target anti-inflammatory effects and mucosal healing within the gastrointestinal tract.
Key facts
- AbbVie entered a global licensing agreement with Nxera Pharma for NXE0033744, an investigational oral EP4 receptor agonist designed to treat inflammatory bowel disease (IBD). source
- Under its global licensing agreement with AbbVie, Nxera will receive $100 million upfront and could earn up to an additional $1.37 billion in development and commercial milestones, plus tiered royalties. source
- AbbVie made a $100 million payment to Regenxbio, which Regenxbio said helped drive its Q3 2026 cash position alongside a public offering. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | contingent | -0.1% | Under its global licensing agreement with AbbVie, Nxera will receive $100 million upfront and could earn up to an additional $1.37 billion… |
| cash | negative | committed | -0.1% | Under its global licensing agreement with AbbVie, Nxera will receive $100 million upfront and could earn up to an additional $1.37 billion… |
| operating_income | negative | contingent | — | Under its global licensing agreement with AbbVie, Nxera will receive $100 million upfront and could earn up to an additional $1.37 billion… |